评估DuoCar20.19.22-D95对复发或难治性B细胞恶性肿瘤的安全性和功效
一项1阶段多中心,开放标签试验,评估DuoCar20.19.22-D95对患有复发或难治性B细胞恶性肿瘤的成年患者的安全性和功效
研究概览
详细说明
剂量升级队列(第1阶段)
这将有3个入学人数:
A组:B-all(预处理或幼稚的汽车)的参与者,B组:B-NHL的参与者(已预处理),C组:B-NHL的参与者
该试验将从三个入学率组中的每个阶段I剂量升级评估开始。 参与者将在剂量1和剂量水平-1或剂量1和剂量1和剂量2级的CAR T细胞中进行治疗。 此阶段将确定随后2期研究的MTD和 /或RP2D。 单个参与者的试验持续时间为DuoCar20.19.22-D95-CAR T细胞输注15年。 输注后,DLT评估将持续到第1阶段剂量升级期间的第30天访问。第1阶段队列的疗效和常规的安全监控将以既定的协议定义的间隔在第2年或直到新的治疗方案开始,以尽快发生的新治疗方案进行。 然后,研究的长期随访部分将成为手术。
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Kansas
-
Westwood、Kansas、美国、66205
- 招聘中
- University of Kansas Cancer Center
-
首席研究员:
- Joseph McGuirk, DO
-
接触:
- Nurse Navigation
- 电话号码:913-945-7552
- 邮箱:CTNurseNav@kumc.edu
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
纳入标准:
- 参与者了解这项研究的能力,以及参与者愿意签署书面知情同意书
- 育种潜力的妇女必须在准备方案开始前48小时进行阴性血清妊娠测试
患者必须具有组织学确认的侵略性B细胞NHL或所有如下所述:
答:复发或难治性B细胞的患者全部i。在研究进入之前和研究进入后的30天内,在最新的疾病评估中,在最近的疾病评估中进行了一种或多种感兴趣的抗原(CD19,CD20,CD22)的演示。
ii。当有CD19和/或CD20和/或CD22表达的免疫表型证据时
iii。 研究条目中的原发性难治性疾病定义为:在研究进入之前从未实现过形态的完整反应。
iv。 研究条目的早期首次复发定义为:疾病在≤18个月时首次缓解持续时间在形态学评估中复发
v。在研究条目中的复发性难治性疾病(首先或以后复发)定义为:启动二线(或更高版本)全身治疗后未达到形态的完全反应
vi。研究条目中的第二或更大复发定义为:第二秒或更高版本后的任何疾病复发(具有两种或多种全身疗法的治疗史)
vii。 超出上述标准以外的其他注意事项:
- 同种异体干细胞移植后复发或难治性疾病的患者必须从HSCT> 100天> 100天才有资格进行研究参与。 此外,在研究进入前至少要停用HSCT后免疫抑制药物
- 如果完成治疗后≥3个月,则允许先前的CAR-T治疗
- 骨髓中的形态学疾病注意:形态学疾病定义为爆炸在骨髓中至少为5%。
B.组织学确认的侵袭性B细胞NHL,包括在2个或更多的先前疗法之后由WHO定义的以下类型:
我。 DLBCL未另有指定; T细胞/组织细胞富含大型B细胞淋巴瘤; DLBCL与慢性炎症有关;老年人的Epstein-Barr病毒(EBV)+ DLBCL;主要皮肤DLBCL,腿类型;或II。 原发纵隔(胸腺)大B细胞淋巴瘤III。 卵泡淋巴瘤3B以及卵泡淋巴瘤向DLBCL的转化也将包括IV。 高级B细胞淋巴瘤诉化学疗法 - 难治性疾病,定义为以下一个或多个:
- 难治性疾病被定义为进行性或稳定疾病,是对自体干细胞移植后12个月内对最新疗法的最佳反应。 LBCL资格需要两种先前的治疗线。 第二线治疗可以是基于化学疗法的,自体干细胞移植或CAR-T。
- 同种异体移植后的复发或难治性疾病,根据入学时,干细胞移植的患者至少是100天的。
患者必须接受2条或更多的适当事先治疗,包括至少:
- 抗CD20单克隆抗体,除非研究者确定肿瘤为CD20-阴性,并且
- 含化学疗法方案的蒽环类
- 对于转化的FL患者,必须接受卵泡淋巴瘤的事先化学疗法,然后在转化为DLBCL VI后患有化学危险疾病。 如果从治疗VII≥3个月≥3个月,则允许先前的CAR T治疗。 根据修订的恶性淋巴瘤的IWG反应标准,至少有1个可测量的病变(Cheson 2007)。 只有在放射治疗后记录进展的情况下,先前已被辐照的病变才能被认为可以测量。复发或难治性的不固定性非霍奇金淋巴瘤I。组织学证实的惰性非霍奇金淋巴瘤,包括1-3B级卵泡淋巴瘤或淋巴瘤或鼻旁边缘区淋巴瘤(均为WHO 2016年分类标准)II。 两次或多个以前的治疗方法后,复发或难治性疾病(每个Lugano标准),III。 以前的治疗方法包括抗CD20单克隆抗体与烷基化剂IV结合。 如果从治疗v≥3个月≥3个月,则允许先前的CAR T治疗。 根据修订的恶性淋巴瘤的IWG反应标准,至少有1个可测量的病变(Cheson 2007)。 只有在放射治疗VI完成后已记录进展的情况下,以前已被辐照的病变才能被视为可测量。 同种异体移植后复发或难治性疾病,提供在入学时至少有100天的干细胞移植和免疫抑制药物的关闭。组织学确认的地幔细胞淋巴瘤,具有细胞周期蛋白D1的过表达或易位的存在(T11:14)II。 疾病复发或难治性至至少2条披风淋巴瘤III的先前方案的先前方案。 先前的疗法必须包括蒽环类药物或含Bendamustine的化学疗法,抗CD20单克隆抗体和BTK抑制剂疗法
- 如果治疗≥3个月≥3个月
- 根据修订的恶性淋巴瘤的IWG反应标准,至少有1个可测量的病变(Cheson 2007)。 只有在辐射治疗完成后已记录进展的情况下,先前已辐照的病变才能被视为可测量
- 同种异体移植后的复发或难治性疾病,根据入学时的干细胞移植患者的≥3个月,在入学前至少4周内进行了免疫抑制药物的关闭。
- 符合白细胞手术的机构标准,或具有以前收集和储存的白细胞术产品的可用性,可满足最低要求
- 东部合作肿瘤学集团(ECOG)的性能状态为0至2。
- 足够的血液学和器官功能注意:良性中性粒细胞减少诊断的患者有资格与1000-1500之间的ANC参与,如果在治疗医师时,试验治疗不会对患者造成过多的感染风险。
- 成人≥18岁,没有年龄上限
- 预期寿命> 2个月
- ≥3个月≥3个月
- 具有育儿潜力的育儿女性和具有育儿潜力的男性必须同意练习性禁止或使用育儿潜力/怀孕部分中列出的避孕形式,从签署知情同意期到DuoCar20.19.22-D95至少12个月,直到CAR阳性T细胞不再通过定量的Polymerase Cation(Qpcr)进行conterative Polymerase Cation(Qpcr)。 男人必须同意在同一时期内不要捐赠精子。
排除标准:
- 患有CLL,Richter转化和Burkitt淋巴瘤的患者
- 活跃的CNS受恶性肿瘤 - CNS3疾病的参与,即CSF≥5中WBC计数的患者在CSF中的患者在CSF中患有全部患者的CSF或通过流式细胞仪或活性CNS参与成像的CSF患者的CSF爆炸)
- 化学疗法以外的淋巴结疗法在输注后2周内
- 筛查前30天内的研究性药物注:研究疗法在研究期间不得在研究期间任何时间使用,直到DuoCar20.19.22-D95之后的第一次进展 汽车输注。
排除以下药物:
- 类固醇:类固醇的治疗剂量必须在白细胞术前> 72小时停止,在DuoCar20.19.22-D95输注之前> 72小时。 但是,允许以下生理替代剂量的类固醇:<12 mg/m2/天氢化可的松或同等
- 免疫抑制:任何其他免疫抑制药物必须在白细胞术前2周停止≥2周,在DuoCar20.19.22-D95输注之前≥2周。 这可能包括检查点抑制剂(单克隆抗体和小分子调节剂)。
- 在输注前2周内,除淋巴结化疗以外的抗增生性疗法
- 用来治疗白血病或淋巴瘤的短作用药(例如酪氨酸激酶抑制剂和羟基脲)必须在白细胞术前> 72小时停止> 72小时,并且在DuoCar20.19.22-d95 Infusion之前> 72小时
- 其他细胞毒性药物,包括每日低剂量或每周的维持化疗,不得在白细胞移动前的2周内以及在Duocar20.19.22-D95输注前2周内给予。
- 抗体的使用包括在输注前4周内或5个半衰期在各个抗体中,以较长者为准。 注意:利妥昔单抗在输注前4周内被排除在外。
- CNS疾病预防或治疗必须在DuoCar20.19.22-D95输液前停止> 1周(例如,胃甲氨蝶呤)
- 在输注后2周内进行了辐射疗法
- 主动复制或事先感染丙型肝炎或活性丙型肝炎(HCV RNA阳性)
- HIV阳性患者(不包括先前汽车中使用的病毒载体引起的假阳性HIV检测)
- 不受控制的急性生命威胁细菌,病毒或真菌感染(例如,输注前血液培养正≤72小时)
- 筛查前6个月内的不稳定的心绞痛和/或心肌梗塞
以下例外情况以前或并发恶性肿瘤:
- 经过足够治疗的基底细胞或鳞状细胞癌(在研究进入之前需要足够的伤口愈合)
- 宫颈或乳房的原位癌进行了经过治疗,并且在研究之前至少没有复发的迹象
- 已完全切除并完全缓解≥5年的主要恶性肿瘤
- 同时参加任何治疗性临床试验(长期随访研究除外)
- 参与这项研究时,当前或预期使用其他抗塑料或研究剂
- 被诊断出患有精神疾病或在社会状况的影响下,这将限制研究人员认为
- 怀孕或母乳喂养
- 对细胞产物的赋形剂的不耐受
- 心律不齐不受医疗管理的控制
- Active Covid-19(遵循ASTCT指南)
- 存在活跃的2至4级急性,广泛的慢性移植抗宿主病(GVHD)或需要全身类固醇
- 活性神经系统免疫或炎症性疾病(例如Guillain-Barré综合征,肌萎缩性侧面硬化症)患者
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Phase 1 (Dose Escalation)
Lymphodepletion: Fludarabine: Days -6 to -3 (4 days total) Cyclophosphamide: Days -6 and -5 (2 days total) Investigational Treatment: DuoCAR20.19.22-D95 will be infused on day # 0 Patients will receive lymphodepletion chemotherapy and receive the CAR T cell infusion on day 0 (or up to day +14 in extenuating clinical conditions). Patients will be hospitalized inpatient period of at least 7 days from the day of the CAR T infusion. |
淋巴清除化疗
使用Miltenyi clinimacsprodigy®封闭转导系统,患者衍生的自体T细胞,慢病毒转导至生成,这是一种靶向细胞表面CD19/20/22的二重率 - car-T细胞。
淋巴结疗法化疗
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
最大耐受剂量(MTD)
大体时间:大约30天
|
MTD定义为紧接≥2/6参与者的剂量水平,其中剂量限制毒性(DLT)。
|
大约30天
|
|
推荐的2阶段剂量(RP2D)
大体时间:大约30天
|
确定使用MTD和DLT。
|
大约30天
|
|
安全:严重不良事件/不良事件的发生率
大体时间:大约30天
|
DuoCar20.19.22-D95的毒性与先前的淋巴结疗法化疗方案结合使用,用CTCAE v 5.0,v 5.0,
|
大约30天
|
|
与治疗相关的死亡率(TRM)
大体时间:大约1年
|
由死亡时没有进行性疾病的定义。
|
大约1年
|
|
外周血样本中的复制能力慢病毒(RCL)的存在
大体时间:大约15年
|
用qpcr测量
|
大约15年
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Duocar的功效20.19.22-D95
大体时间:长达24个月
|
由WHO定义的骨髓确定的CR/PR速率定义的总体反应率和B细胞NHL中的Lugano响应标准。
|
长达24个月
|
|
与DuoCar20.19.22-D95有关的安全性
大体时间:大约15年
|
为了评估长期安全风险,根据与基因疗法有关的指南,该指南通过可能与DuoCar的特殊兴趣的延迟不良事件衡量
|
大约15年
|
|
药理学(扩展动力学)
大体时间:28天
|
DuoCar20.19.22-D95的扩展动力学随着时间的流逝和/或流式细胞仪测量,Winnonlin 8.4
|
28天
|
|
Manufacturing Feasibility of Miltenyi CliniMACS Prodigy (By number of participants)
大体时间:2 weeks
|
To assess the Miltenyi CliniMACS Prodigy® closed transduction system for manufacturing feasibility of DuoCAR20.19.22-D95 throughout dose escalation and efficacy.
For evaluation of feasibility, the number of participants which can successfully manufacture the targeted dose number will be determined and reported by dose level for the three enrollment groups.
|
2 weeks
|
|
Blood DuoCAR20.19.22-D95 concentrations (PCR)
大体时间:approximately 2 years
|
determined by PCR and/or flow cytometry
|
approximately 2 years
|
|
Blood DuoCAR20.19.22-D95 concentrations (Non-parametric PK parameters)
大体时间:approximately 2 years
|
Non-parametric pharmacokinetic data analysis will be performed on resultant blood DuoCAR20.19.22-D95 concentration-time data using WinNonlin 8.4.
|
approximately 2 years
|
|
Blood DuoCAR20.19.22-D95 concentrations (time data)
大体时间:approximately 2 years
|
The frequency (n,%) of observed concentrations below the lower limit of quantitation (LLOQ), reported as zero, will be described for each sampling timepoint
|
approximately 2 years
|
|
Blood DuoCAR20.19.22-D95 mean concentrations
大体时间:approximately 2 years
|
Mean concentrations will be provided for blood DuoCAR20.19.22-D95 concentration-time data
|
approximately 2 years
|
合作者和调查者
调查人员
- 首席研究员:Joseph McGuirk, D.O.、University of Kansas Medical Center
出版物和有用的链接
一般刊物
- Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Espanol de Medula Osea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800.
- Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. doi: 10.1200/JCO.2006.09.2403. Epub 2007 Jan 22.
- Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, June CH. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015 Sep 2;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.
- Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015 Feb 7;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.
- Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92. doi: 10.1073/pnas.0806075105. Epub 2008 Sep 25.
- Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017 Jun 22;129(25):3322-3331. doi: 10.1182/blood-2017-02-769208. Epub 2017 Apr 13.
- Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.
- Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
- Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, Shimoni A, Nagler A, Toren A, Jacoby E. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019 Oct;54(10):1643-1650. doi: 10.1038/s41409-019-0487-3. Epub 2019 Feb 26.
- Muller SM, Ege M, Pottharst A, Schulz AS, Schwarz K, Friedrich W. Transplacentally acquired maternal T lymphocytes in severe combined immunodeficiency: a study of 121 patients. Blood. 2001 Sep 15;98(6):1847-51. doi: 10.1182/blood.v98.6.1847.
- Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20;23(18):4070-8. doi: 10.1200/JCO.2005.12.516. Epub 2005 Mar 14.
- Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. doi: 10.1016/j.jtct.2023.03.006. Epub 2023 Mar 9.
- Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.
- Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
- Dioverti V, Boghdadly ZE, Shahid Z, Waghmare A, Abidi MZ, Pergam S, Boeckh M, Dadwal S, Kamboj M, Seo S, Chemaly RF, Papanicolaou GA. Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022). Transplant Cell Ther. 2022 Dec;28(12):810-821. doi: 10.1016/j.jtct.2022.09.002. Epub 2022 Sep 11.
- Hedger MP, Meinhardt A. Local regulation of T cell numbers and lymphocyte-inhibiting activity in the interstitial tissue of the adult rat testis. J Reprod Immunol. 2000 Oct-Nov;48(2):69-80. doi: 10.1016/s0165-0378(00)00071-1.
- Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives S, Boyer MW, Hiramatsu H, Yanik GA, Driscoll T, Myers GD, Bader P, Baruchel A, Buechner J, Stefanski HE, Kalfoglou C, Nguyen K, Waldron ER, Thudium Mueller K, Maier HJ, Kari G, Grupp SA. Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. Blood Cancer Discov. 2022 Jan;3(1):66-81. doi: 10.1158/2643-3230.BCD-21-0095. Epub 2021 Dec 1.
- Rossoff J, Baggott C, Prabhu S, Pacenta H, Phillips CL, Stefanski H, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras N, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Kunicki M, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood. 2021 Nov 25;138(21):2138-2142. doi: 10.1182/blood.2021012392. No abstract available.
- Laetsch TW, Myers GD, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, Buechner J, De Moerloose B, Davis KL, Nemecek E, Driscoll T, Mechinaud F, Boissel N, Rives S, Bader P, Peters C, Sabnis HS, Grupp SA, Yanik GA, Hiramatsu H, Stefanski HE, Rasouliyan L, Yi L, Shah S, Zhang J, Harris AC. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 2019 Dec;20(12):1710-1718. doi: 10.1016/S1470-2045(19)30493-0. Epub 2019 Oct 9.
- Schneider D, Xiong Y, Wu D, Hu P, Alabanza L, Steimle B, Mahmud H, Anthony-Gonda K, Krueger W, Zhu Z, Dimitrov DS, Orentas RJ, Dropulic B. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci Transl Med. 2021 Mar 24;13(586):eabc6401. doi: 10.1126/scitranslmed.abc6401.
- Dekker L, Calkoen FG, Jiang Y, Blok H, Veldkamp SR, De Koning C, Spoon M, Admiraal R, Hoogerbrugge P, Vormoor B, Vormoor HJ, Visscher H, Bierings M, Van Der Vlugt M, Van Tinteren H, Nijstad AL, Huitema ADR, Van Der Elst KCM, Pieters R, Lindemans CA, Nierkens S. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood Adv. 2022 Apr 12;6(7):1969-1976. doi: 10.1182/bloodadvances.2021006700.
- Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity. 2001 Sep;15(3):445-55. doi: 10.1016/s1074-7613(01)00191-1.
- Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol. 2000 Sep 15;165(6):3043-50. doi: 10.4049/jimmunol.165.6.3043.
- Maxwell JR, Weinberg A, Prell RA, Vella AT. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol. 2000 Jan 1;164(1):107-12. doi: 10.4049/jimmunol.164.1.107.
- Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020 Mar;17(3):147-167. doi: 10.1038/s41571-019-0297-y. Epub 2019 Dec 17.
- Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020 Apr 1;130(4):1586-1594. doi: 10.1172/JCI129208.
- Moreno-Cortes E, Franco-Fuquen P, Garcia-Robledo JE, Forero J, Booth N, Castro JE. ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype. Front Oncol. 2023 Aug 18;13:1200914. doi: 10.3389/fonc.2023.1200914. eCollection 2023.
- Poe JC, Minard-Colin V, Kountikov EI, Haas KM, Tedder TF. A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice. J Immunol. 2012 Sep 1;189(5):2318-25. doi: 10.4049/jimmunol.1201000. Epub 2012 Jul 23.
- Fruman DA. Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling. Curr Opin Immunol. 2004 Jun;16(3):314-20. doi: 10.1016/j.coi.2004.03.014.
- Rogel A, Willoughby JE, Buchan SL, Leonard HJ, Thirdborough SM, Al-Shamkhani A. Akt signaling is critical for memory CD8+ T-cell development and tumor immune surveillance. Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):E1178-E1187. doi: 10.1073/pnas.1611299114. Epub 2017 Jan 30.
- Gravestein LA, Nieland JD, Kruisbeek AM, Borst J. Novel mAbs reveal potent co-stimulatory activity of murine CD27. Int Immunol. 1995 Apr;7(4):551-7. doi: 10.1093/intimm/7.4.551.
- Haas KM, Sen S, Sanford IG, Miller AS, Poe JC, Tedder TF. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol. 2006 Sep 1;177(5):3063-73. doi: 10.4049/jimmunol.177.5.3063.
- Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology. 2012 Jul 1;1(4):458-466. doi: 10.4161/onci.19855.
- Majzner RG, Mackall CL. Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov. 2018 Oct;8(10):1219-1226. doi: 10.1158/2159-8290.CD-18-0442. Epub 2018 Aug 22.
- Shah NN, Maatman T, Hari P, Johnson B. Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. Front Oncol. 2019 Mar 12;9:146. doi: 10.3389/fonc.2019.00146. eCollection 2019.
- Holland EM, Molina JC, Dede K, Moyer D, Zhou T, Yuan CM, Wang HW, Stetler-Stevenson M, Mackall C, Fry TJ, Panch S, Highfill S, Stroncek D, Little L, Lee DW, Shalabi H, Yates B, Shah N. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. J Immunother Cancer. 2022 May;10(5):e004483. doi: 10.1136/jitc-2021-004483.
- Cao Y, Xiao Y, Wang N, Wang G, Huang L, Hong Z, Meng L, Zhou X, Wang J, Yang Y, Xu H, Zhang S, Xiao M, Chen L, Zheng M, Li C, Mao X, Gu C, Zhang T, Zhang Y, Zhou J. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas. Transplant Cell Ther. 2021 Nov;27(11):910.e1-910.e11. doi: 10.1016/j.jtct.2021.08.012. Epub 2021 Aug 20.
- Pan J, Niu Q, Deng B, Liu S, Wu T, Gao Z, Liu Z, Zhang Y, Qu X, Zhang Y, Liu S, Ling Z, Lin Y, Zhao Y, Song Y, Tan X, Zhang Y, Li Z, Yin Z, Chen B, Yu X, Yan J, Zheng Q, Zhou X, Gao J, Chang AH, Feng X, Tong C. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia. 2019 Dec;33(12):2854-2866. doi: 10.1038/s41375-019-0488-7. Epub 2019 May 20.
- Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Gine E, Durrant S, Kneissl M, Luu KT, Hua SY, Boni J, Vandendries E, Dang NH. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013 Feb 10;31(5):573-83. doi: 10.1200/JCO.2012.42.7211. Epub 2013 Jan 7.
- Rigaud C, Auperin A, Jourdain A, Haouy S, Couec ML, Aladjidi N, Gandemer V, Lambliotte A, Plat G, Landman-Parker J, Michon J, Leblanc T, Patte C, Minard-Colin V. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study. Pediatr Blood Cancer. 2019 Sep;66(9):e27873. doi: 10.1002/pbc.27873. Epub 2019 Jun 17.
- Hochberg J, El-Mallawany NK, Abla O. Adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. 2016 May;173(4):637-50. doi: 10.1111/bjh.14074. Epub 2016 Apr 12.
- Anoop P, Sankpal S, Stiller C, Tewari S, Lancaster DL, Khabra K, Taj MM. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. Leuk Lymphoma. 2012 Oct;53(10):1882-8. doi: 10.3109/10428194.2012.677534. Epub 2012 Apr 23.
- Egan G, Goldman S, Alexander S. Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies. Br J Haematol. 2019 Jun;185(6):1071-1085. doi: 10.1111/bjh.15734. Epub 2019 Jan 6.
- Cairo M, Auperin A, Perkins SL, Pinkerton R, Harrison L, Goldman S, Patte C. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group. Br J Haematol. 2018 Sep;182(6):859-869. doi: 10.1111/bjh.15491. Epub 2018 Jul 9.
- Moleti ML, Testi AM, Foa R. Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2020 Jun;189(5):826-843. doi: 10.1111/bjh.16461. Epub 2020 Mar 6.
- Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Munster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 1;120(23):3660-8. doi: 10.1002/cncr.28930. Epub 2014 Jul 17.
- Ram R, Wolach O, Vidal L, Gafter-Gvili A, Shpilberg O, Raanani P. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol. 2012 May;87(5):472-8. doi: 10.1002/ajh.23149. Epub 2012 Mar 3.
- Essig S, Li Q, Chen Y, Hitzler J, Leisenring W, Greenberg M, Sklar C, Hudson MM, Armstrong GT, Krull KR, Neglia JP, Oeffinger KC, Robison LL, Kuehni CE, Yasui Y, Nathan PC. Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2014 Jul;15(8):841-51. doi: 10.1016/S1470-2045(14)70265-7. Epub 2014 Jun 19.
- Hunger SP, Baruchel A, Biondi A, Evans WE, Jeha S, Loh M, Moericke A, Pieters R, Relling MV, Schmiegelow K, Schrappe M, Silverman LB, Stanulla M, Valsecchi MG, Vora A, Pui CH. The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011. Pediatr Blood Cancer. 2013 Feb;60(2):344-8. doi: 10.1002/pbc.24354. Epub 2012 Sep 28. No abstract available.
- Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HM. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010 Mar 1;116(5):1165-76. doi: 10.1002/cncr.24862.
- Gill S, Carney D, Ritchie D, Wolf M, Westerman D, Prince HM, Januszewicz H, Seymour JF. The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol. 2010 Feb;21(2):331-334. doi: 10.1093/annonc/mdp297. Epub 2009 Jul 22.
- Levine JE, Grupp SA, Pulsipher MA, Dietz AC, Rives S, Myers GD, August KJ, Verneris MR, Buechner J, Laetsch TW, Bittencourt H, Baruchel A, Boyer MW, De Moerloose B, Qayed M, Davies SM, Phillips CL, Driscoll TA, Bader P, Schlis K, Wood PA, Mody R, Yi L, Leung M, Eldjerou LK, June CH, Maude SL. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. J Immunother Cancer. 2021 Aug;9(8):e002287. doi: 10.1136/jitc-2020-002287.
- Schuster, SJ, Svoboda J, Nasta SD, et al, Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas. Blood, 2015. 126(23): p. 183-183.
- Jourdain A, Auperin A, Minard-Colin V, Aladjidi N, Zsiros J, Coze C, Gandemer V, Bertrand Y, Leverger G, Bergeron C, Michon J, Patte C; SFCE LNH Committee. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Societe Francaise des Cancers de l'Enfant study. Haematologica. 2015 Jun;100(6):810-7. doi: 10.3324/haematol.2014.121434. Epub 2015 Feb 27.
- Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD Jr, Scholler J, Scholler N, Bonneau R, June CH. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood. 2014 Aug 14;124(7):1070-80. doi: 10.1182/blood-2013-10-535245. Epub 2014 Jul 1.
- Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, Plotkin J, Sadelain M. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell. 2015 Oct 12;28(4):415-428. doi: 10.1016/j.ccell.2015.09.004.
- Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015 Jun;21(6):581-90. doi: 10.1038/nm.3838. Epub 2015 May 4.
- National Institute of Health/National Cancer Institute - Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE). URL: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_60 Accessed 01-26-2022
- Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, Horowitz MM, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 Nov 10;4(21):5414-5424. doi: 10.1182/bloodadvances.2020003092.
- Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014 Sep 20;32(27):3048-58. doi: 10.1200/JCO.2013.53.5229.
- Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Mackall CL, Laetsch TW, Schultz LM, Curran KJ. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022 Apr 12;6(7):1961-1968. doi: 10.1182/bloodadvances.2021006418.
- Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, June CH. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 2016 Feb 16;44(2):380-90. doi: 10.1016/j.immuni.2016.01.021.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- STUDY00161006
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.